Zovegalisib for lymphatic abnormalities

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Jan 2025: Trial registered, NCT06789913
  2. 13 Jun 2025: Trial started, NCT06789913

The trials

NCT06789913: A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

State
Under way
Phase
Phase 2
People
277 planned
Started
13 Jun 2025
Primary completion
Jul 2031
Arms
Part 1, Group 1, Part 1, Group 2, Part 1, Group 3, Part 2, Group 1, Part 2, Group 2, Part 2, Group 3, Part 3, Arm 1
Results
None posted
  1. 23 Jan 2025: Trial registered
  2. 13 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.